Pharmacyclics About
Pharmacyclics Pharmacyclics, Inc. is a pharmaceutical company
developing a patented new class of drugs intended to treat cancer
and atherosclerosis.
The pharmaceutical agents, known as texaphyrins, are synthetic small molecules
designed to possess a variety of biological and chemical properties. Texaphyrins
are designed to selectively concentrate in diseased tissue such as
tumor cells and atherosclerotic plaque inside blood vessels. Inside diseased
cells, texaphyrins block crucial steps in cellular metabolism and disrupt bioenergetic
processes. Motexafin gadolinium --this is the company's lead
anti-cancer product candidate, currently is in Phase 3 clinical trials. It has
potentially broad applications in oncology and is designed to: selectively target
cancer cells; and be detected by magnetic resonance imaging (MRI) allowing visualization
of the drug in tumors. Motexafin
lutetium -- Pharmacyclics is investigating the potential of texaphyrin
treatment, including the combination of motexafin lutetium and interventional
delivery of light-based therapy, to reduce or eliminate “vulnerable plaque,” the
cause of serious cardiac events. Key
Statistics for Pharmacyclics